Two Sigma Investments LP Increases Position in Eli Lilly and Company (NYSE:LLY)

Two Sigma Investments LP increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 61.6% during the fourth quarter, Holdings Channel reports. The institutional investor owned 322,690 shares of the company’s stock after acquiring an additional 122,954 shares during the period. Eli Lilly and Company comprises about 0.5% of Two Sigma Investments LP’s portfolio, making the stock its 16th biggest position. Two Sigma Investments LP’s holdings in Eli Lilly and Company were worth $249,117,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FPC Investment Advisory Inc. grew its holdings in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after acquiring an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new stake in Eli Lilly and Company during the fourth quarter worth $48,000. Compass Financial Services Inc acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $50,000. Fiduciary Advisors Inc. purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $58,000. Finally, Bellwether Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth $66,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.13% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $757.23 on Monday. The business’s 50-day moving average price is $797.84 and its 200 day moving average price is $805.69. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a market capitalization of $717.65 billion, a PE ratio of 64.67, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. During the same quarter in the previous year, the company earned $2.58 earnings per share. The company’s revenue was up 45.2% on a year-over-year basis. On average, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.79%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Finally, The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.